Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
King International Investment Buyback Yield % Chart
HKSE:00928 vs TMO, DHR, IDXX: Buyback Yield % Comparison
For the Diagnostics & Research subindustry, King International Investment's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
King International Investment Buyback Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, King International Investment's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where King International Investment's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
King International Investment (HKSE:00928) has a Buyback Yield % of 0.00 as of Aug. 24, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on King International Investment and its competitors. According to the industry distribution chart, King International Investment ranks #999999 out of 81 companies in the Medical Diagnostics & Research industry.
Is King International Investment's Buyback Yield % too high?
King International Investment's current Buyback Yield % is 0.00. Based on the distribution chart, King International Investment ranks #999999 out of 81 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, King International Investment has a GF Score™ of 33/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does King International Investment's Buyback Yield % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, King International Investment ranks #999999 out of 81 companies for Buyback Yield %. This places King International Investment in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Diagnostics & Research company?
A good Buyback Yield % depends on the Medical Diagnostics & Research industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on King International Investment and its competitors. King International Investment's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is King International Investment stock overvalued right now?
Based on GuruFocus' analysis, King International Investment (HKSE:00928) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.04, compared to a current price of HK$0.10 — trading 157.5% above its estimated fair value. The current Buyback Yield % is 0.00. King International Investment's overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For King International Investment (HKSE:00928), the current Buyback Yield % is 0.00 as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is King International Investment (HKSE:00928) Overvalued in 2026?
Based on GuruFocus' analysis, King International Investment stock appears to be overvalued.
The current stock price of HK$0.10 is trading 157.5% above its estimated GF Value™ of HK$0.04.
GuruFocus considers King International Investment to be Significantly Overvalued.
Key valuation signals for HKSE:00928:
Buyback Yield %: 0.00
GF Value™: HK$0.04 vs. price of HK$0.10 (157.5% above fair value)
No single metric tells the full story. See the HKSE:00928 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
King International Investment Ltd is an investment holding company. Its operating segments include healthcare products and services, money lending, and liquor sales, with the majority of revenue generated from the liquor sales segment. The group provides genetic testing and develops domestic healthcare equipment services. Leveraging its strengths, the group integrates health data analysis software with healthcare equipment to offer new healthcare services and products. Geographically, it derives the majority of its revenue from the PRC.
33GF Score
Get the complete analysis for HKSE:00928
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:00928 has been successfully added to your 
